All In Biotech

Drug Trial Radar · NCT07101783

A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Investigation of Pharmacokinetic Properties of Single Doses of NNC0662-0419 in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Aug 1, 2025

Primary completion

Oct 31, 2025

Study completion Oct 31, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose. And also look into how safe and how well the study medicine is tolerated in people living with overweight or obesity. NNC0662-0419 is a new medicine which cannot be prescribed by doctors. NNC0662-0419 is currently being tested in humans and the dose participants will receive has been found safe and tolerable. Participants will get a single dose of NNC0662-0419 given by study staff as a single injection under participants skin. Like all medicines, the study medicine may have side effects. The study will last up to 2 months.

Conditions

  • Overweight
  • Obesity

Interventions

  • NNC0662-0419Drug

    Participants will receive NNC0662-0419 subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC; The area under the NNC0662-0419 plasma concentration-time curveTime frame: From pre-dose on Day 1 until completion of the end of study visit (Day 29)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical LA, Inc.

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.